Search Results
A Special Surprise for Pediatric Cancer Patient Counting Down the Days until Treatment Ends
"A Style for Every Smile” Campaign is Brightening the Faces of Pediatric Cancer Patients like 4-Year-Old Sasha Nationwide
At the tender age of four, Sasha has endured more than most of us will in a lifetime. In October 2017, at just two years old, she was diagnosed with acute lymphoblastic leukemia, a diagnosis no parent wants to hear.
"It sounds so stereotypical, but I just didn't believe it. I was completely in denial,” says Sasha’s mom, Randi.
Idelalisib
Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Mercaptopurine
Mercaptopurine is FDA approved to treat people who have acute lymphoblastic leukemia as part of a combination regimen.
Busulfan
Busulfan is FDA approved in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for people who have chronic myeloid leukemia.
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Rylaze™ is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Asciminib
Asciminib is indicated for the treatment of adult patients with:
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). - Ph+ CML in CP with the T315I mutation.
Glasdegib
Glasdegib is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.
Salesforce Doubles Million Dollar Impact on Cancer
They say, “Teamwork makes the dream work” and the 2016 Light The Night Salesforce team’s March to a Million initiative has proved this is true. As LLS’s longtime Light The Night partner, the team of more than 1,880 participants from across the U.S. went above and beyond this year to fight blood cancer. Not only did they meet their $1 million dollar fundraising goal, but Salesforce has generously offered to match it— bringing their total amount raised to more than $2 million for LLS’s goal to create a world without blood cancers!
Targeted Therapy focus of LLS-hosted Symposium at ASH
As researchers gain greater understanding of how cancer works, they are becoming more adept at developing precisely targeted therapies that go after the tumor cells while sparing the healthy cells.
Today The Leukemia & Lymphoma Society (LLS) kicked off the 57th American Society of Hematology (ASH) Annual Meeting in Orlando with a satellite symposium entitled, “Molecularly Targeted Therapies for Hematologic Malignancies.”
LLS Aligns with “Moonshot” Goal of Putting Patients at the Center of Cancer Care
The national “Moonshot” initiative is repeatedly making news headlines as the $1 billion effort designed to eliminate cancer has groundbreaking potential. Led by Vice President Joe Biden, the effort is focused on accelerating research and making more therapies available – and blood cancer patients have much to gain.
I recently joined an expert panel at the annual Milken Institute Global Conference, “Promise of the Cancer Moonshot,” to share The Leukemia & Lymphoma Society’s (LLS) perspective about what needs to be done to move this effort forward.
Burlington Stores Surpasses $3 Million Goal to Help Fight Blood Cancer
Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) 14th consecutive year of partnership in the fight against blood cancers was a huge success. As LLS’s #1 national corporate partner and honored friend, Burlington, the national off-price retailer, beat its $3 million goal for its annual Light The Night Walk campaign by a long shot, raising an astonishing $3.35 million. This marks one of the retailer’s most successful and longest running philanthropic campaigns.
MY FIRST 100 DAYS AS LLS PRESIDENT & CEO
Dear Friends,
I’m just over 100 days into my new role as President & CEO of The Leukemia & Lymphoma Society (LLS) and I want to take this moment to say how grateful and proud I am to work alongside all of you in service of blood cancer patients and their families. It’s been great meeting many of you as I travel to our regions and meet with departments throughout the country. And I look forward to meeting many more of you in the months ahead.
#ASH18: Beating AML
Sunday marked a significant milestone for The Leukemia & Lymphoma Society (LLS) and the patients we help. Here at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, a conference attended by more than 30,000 scientists from around the world, we unveiled the first results from our groundbreaking precision medicine Beat AML Master Clinical Trial. To date, more than 356 patients have been screened for this trial.
Mitoxantrone
Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. Mitoxantrone is a dark blue solution that may cause urine to appear blue-green. It may also cause the whites of the eyes to turn a blue color. These effects are normal and last for only 1 or 2 days after each dose is given. This medicine often causes a temporary loss of hair. After treatment with mitoxantrone has ended, normal hair growth should return.
Teniposide
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.
Vinblastine
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Asparaginase erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
Bendamustine hydrochloride
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Chlorambucil
Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.
Idarubicin
Idarubicin is FDA approved in combination with other antileukemic drugs to treat people who have acute myeloid leukemia in adults.